Altering the rehabilitation environment to improve stroke survivor activity: A Phase II trial.

Stroke activity clinical trial environmental enrichment recovery rehabilitation

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
03 2022
Historique:
pubmed: 20 3 2021
medline: 23 3 2022
entrez: 19 3 2021
Statut: ppublish

Résumé

Environmental enrichment involves organization of the environment and provision of equipment to facilitate engagement in physical, cognitive, and social activities. In animals with stroke, it promotes brain plasticity and recovery. To assess the feasibility and safety of a patient-driven model of environmental enrichment incorporating access to communal and individual environmental enrichment. A nonrandomized cluster trial with blinded measurement involving people with stroke ( The experimental group ( This patient-driven model of environmental enrichment was feasible and safe. However, the very modest increase in activity by people with stroke, and the lack of benefit in clinical outcomes three months after stroke do not provide justification for an efficacy trial.

Sections du résumé

BACKGROUND
Environmental enrichment involves organization of the environment and provision of equipment to facilitate engagement in physical, cognitive, and social activities. In animals with stroke, it promotes brain plasticity and recovery.
AIMS
To assess the feasibility and safety of a patient-driven model of environmental enrichment incorporating access to communal and individual environmental enrichment.
METHODS
A nonrandomized cluster trial with blinded measurement involving people with stroke (
RESULTS
The experimental group (
CONCLUSIONS
This patient-driven model of environmental enrichment was feasible and safe. However, the very modest increase in activity by people with stroke, and the lack of benefit in clinical outcomes three months after stroke do not provide justification for an efficacy trial.

Identifiants

pubmed: 33739202
doi: 10.1177/17474930211006999
doi:

Types de publication

Clinical Trial Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

299-307

Auteurs

Heidi Janssen (H)

5260Hunter New England Local Health District, Australia.
Hunter Medical Research Institute, Australia.
College of Health, Medicine and Wellbeing, University of Newcastle, Australia.

Louise Ada (L)

Faculty of Medicine and Health, University of Sydney, Australia.

Sandy Middleton (S)

Faculty of Health Sciences Department, Nursing Research Institute, Australia.
Department of Medicine, University of Melbourne, Australia.

Michael Pollack (M)

5260Hunter New England Local Health District, Australia.
Hunter Medical Research Institute, Australia.
College of Health, Medicine and Wellbeing, University of Newcastle, Australia.

Michael Nilsson (M)

Hunter Medical Research Institute, Australia.
College of Health, Medicine and Wellbeing, University of Newcastle, Australia.

Leonid Churilov (L)

Department of Medicine, University of Melbourne, Australia.

Jannette Blennerhassett (J)

Health Independence Program and Physiotherapy Department, Austin Health, Australia.

Steven Faux (S)

Departments of Rehabilitation Medicine and Pain Medicine, St Vincent's Hospital, Australia.

Peter New (P)

Department of Medicine & Rehabilitation and Aged Services Program, 2538Monash Health, Australia.
Monash Medical School & Department of Epidemiology and Preventive Medicine, School of Public Health & Preventive Medicine, Monash University, Australia.

Annie McCluskey (A)

Faculty of Medicine and Health, University of Sydney, Australia.

Neil J Spratt (NJ)

5260Hunter New England Local Health District, Australia.
Hunter Medical Research Institute, Australia.
College of Health, Medicine and Wellbeing, University of Newcastle, Australia.

Julie Bernhardt (J)

The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH